Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Incidental Thyroid Cancer in Cases With Inflammatory Thyroid Lesion (Thyroid cancer)

11. juni 2026 opdateret af: Abdelrahman Mohamed Salah, Minia University

Incidental Thyroid Cancer in Patients With Inflammatory Thyroid Lesions: A Cohort Study From a Tertiary Care Center

This study aim to assess for the incidence of thyroid cancer in patients with autoimmune thyroiditis (Inflammatory thyroid Lesions)

Studieoversigt

Detaljeret beskrivelse

The relationship between chronic inflammation and carcinogenesis is well established in multiple organ systems, including the liver, stomach, and colon. In the thyroid, chronic lymphocytic infiltration may create a pro-inflammatory microenvironment that promotes cellular proliferation, DNA damage, and oncogenic transformation. Several studies have suggested an increased risk of thyroid cancer, particularly papillary thyroid carcinoma (PTC), in patients with Hashimoto thyroiditis

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

200

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Minya Governorate
      • Minya, Minya Governorate, Egypten, 61611
        • Faculty of Medicine

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. All types of autoimmune thyroiditis, including:

    • Graves' disease
    • Toxic multinodular goiter (TMNG)
    • Toxic nodule (TN)
    • Hashimoto thyroiditis
    • Unspecified toxic nodular goiter
  2. Age between 18 and 60 years
  3. Underwent thyroid surgical operation (lobectomy or total thyroidectomy)

Exclusion Criteria:

  1. Patients with known differentiated thyroid cancer before surgery
  2. Recurrent thyroid disease (previous thyroid surgery)
  3. Patients unfit for operation (American Society of Anesthesiologists grade IV or V)
  4. Incomplete histopathological data
  5. Patients with medullary thyroid carcinoma or anaplastic thyroid cancer

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: Inflammatory thyroid lesions
The presence of thyroiditis was determined considering histological diagnosis taken post-surgery, and we considered the correlation between any presence of thyroiditis and all Differentiated thyroid cancer, taken from the histopathological examination after pathologic analysis.
Diagnosis of differentiated thyroid cancer: The presence of thyroid cancer was determined based on histopathological examination of the resected specimen

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
• Incidence of incidental differentiated thyroid cancer with autoimmune thyroiditis
Tidsramme: At time of surgery (postoperative histopathology)

Title: Incidence of incidental differentiated thyroid cancer

Unit of measure: % of patients (proportion)

Metric/method: Histopathological examination of surgical specimen

At time of surgery (postoperative histopathology)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of incidental differentiated thyroid cancer by autoimmune thyroiditis subtype
Tidsramme: At time of surgery

Unit of Measure

Percentage of patients within each subtype (Hashimoto thyroiditis, Graves' disease, toxic nodular goiter)

Metric / Method

Histopathological classification of thyroiditis subtype and cancer diagnosis; comparison using Chi-square test or Fisher's exact test

At time of surgery
Outcome 3A: Age comparison
Tidsramme: At time of surgery
Outcome Measure Title Mean age difference between patients with and without incidental differentiated thyroid cancer Unit of Measure Years (mean ± standard deviation) Metric / Method Unpaired Student's t-test or Mann-Whitney U test
At time of surgery
Outcome 3B: Sex distribution
Tidsramme: Preoperative (within 30 days before surgery)
Field Entry Outcome Measure Title Proportion of patients with positive anti-thyroid peroxidase (anti-TPO) antibodies who have incidental differentiated thyroid cancer Unit of Measure Percentage of patients Metric / Method Serological testing (anti-TPO antibodies measured by immunoassay); Chi-square test or logistic regression for association
Preoperative (within 30 days before surgery)
Secondary Outcome 4 - Tumor characteristics Outcome 4A: Tumor size
Tidsramme: At time of surgery
Outcome Measure Title Maximum tumor diameter in incidental differentiated thyroid cancers Unit of Measure Centimeters (mean ± standard deviation and range) Metric / Method Pathological measurement of surgical specimen
At time of surgery
Outcome 4B: Microcarcinoma proportion
Tidsramme: At time of surgery
Outcome Measure Title Proportion of incidental thyroid cancers that are microcarcinomas (≤1 cm) Unit of Measure Percentage of patients with incidental cancer Metric / Method Pathological measurement; defined as tumor size ≤1 cm
At time of surgery
Outcome 4C: Lymph node metastasis
Tidsramme: At time of surgery
Outcome Measure Title Proportion of patients with incidental differentiated thyroid cancer who have lymph node metastasis Unit of Measure Percentage of patients with incidental cancer Metric / Method Histopathological examination of central neck dissection specimens
At time of surgery
Outcome 4D: Multifocality
Tidsramme: At time of surgery
Outcome Measure Title Proportion of patients with incidental differentiated thyroid cancer who have multifocal disease Unit of Measure Percentage of patients with incidental cancer Metric / Method Histopathological examination (two or more distinct tumor foci)
At time of surgery
Outcome 3E: Extrathyroidal extension
Tidsramme: At time of surgery
Outcome Measure Title Proportion of patients with incidental differentiated thyroid cancer who have extrathyroidal extension Unit of Measure Percentage of patients with incidental cancer Metric / Method Histopathological examination (minimal or extensive extension)
At time of surgery

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. februar 2025

Primær færdiggørelse (Faktiske)

1. februar 2026

Studieafslutning (Faktiske)

31. maj 2026

Datoer for studieregistrering

Først indsendt

6. juni 2026

Først indsendt, der opfyldte QC-kriterier

11. juni 2026

Først opslået (Faktiske)

17. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. juni 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The data will be available upon a reasonable request from the corresponding author.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Papillær skjoldbruskkirtelkræft

Kliniske forsøg med total thyroidectomy

Abonner